Imugene Limited (AU:IMU) has released an update.
Imugene Limited, a company specializing in cancer immunotherapies, has cautioned investors that the information presented at the Bell Potter Emerging Leaders Conference should not be taken as personal investment advice, emphasizing that investment decisions should be made with professional advice. The accuracy and completeness of the presentation are not guaranteed, and the company and its representatives are not liable for any losses incurred from reliance on the information provided. The company has also noted that the presentation does not constitute an offer in any jurisdiction where such an offer would be illegal.
For further insights into AU:IMU stock, check out TipRanks’ Stock Analysis page.
